Laura Tadvalkar - Jul 18, 2024 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: Director
Signature: /s/ Shane Ward, Attorney-in-Fact
Stock symbol: CDTX
Transactions as of: Jul 18, 2024
Transactions value $: $0
Form type: 4
Date filed: 7/19/2024, 04:38 PM
Previous filing: Apr 30, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDTX	Stock Option (right to buy)	Award	$0	+2.13K		$0.00	2.13K	Jul 18, 2024	Common Stock	2.13K	$12.64	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.